Clinical Trial

A Phase Ib Study of HW211026 Ointment in Patients With Actinic Keratosis.

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 6, 2026 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a phase Ib study to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) characteristics of HW211026 ointment after single or multiple topical administrations in patients with actinic keratosis.
Trial Details
NCT Number NCT07318675
Lead Sponsor Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Conditions Actinic Keratosis (AK)
Enrollment 40 participants
Start Date 2025-12-25
Primary Completion 2026-03 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2026-01-06